Biotech Breakthroughs: Enlivex and bioAffinity on RedChip Small Stocks, Big Money™

The biotechnology sector is abuzz with innovation and potential, as companies like Enlivex Therapeutics and bioAffinity Technologies continue to make strides in their respective fields. These two companies will be featured on the RedChip Small Stocks, Big Money™ show on Bloomberg TV, providing investors with an exclusive opportunity to learn about their cutting-edge technologies and growth prospects.

Enlivex Therapeutics, a clinical-stage macrophage reprogramming immunotherapy company, is developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. This innovative approach aims to address critical medical challenges, including life-threatening conditions such as sepsis and debilitating diseases like osteoarthritis. With promising Phase I/II clinical trial results in multiple indications, including knee osteoarthritis and psoriatic arthritis, Enlivex is advancing Allocetra™ as a potential game-changer for millions of patients globally.



In 2024, Enlivex initiated a multi-country, randomized trial evaluating Allocetra™ in up to 160 patients with moderate to severe knee osteoarthritis, with key data expected by Q3 2025. This trial, along with other ongoing studies, positions Enlivex for significant growth and potential breakthroughs in the coming years.

bioAffinity Technologies, on the other hand, is addressing the urgent need for noninvasive, accurate early-stage cancer diagnosis through its first product, CyPath® Lung. This test improves early-stage detection of lung cancer, leading to increased survival, fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs. In October 2024, bioAffinity secured a U.S. Federal Supply Schedule contract for CyPath® Lung, making the test available to U.S. veterans and federal health service patients. This contract is expected to accelerate sales growth in the quarters ahead, as it opens up access to a large patient population and increases the test's visibility within the federal healthcare system.

The global lung cancer diagnostics market is expected to grow at a CAGR of 8.5% from 2021 to 2028, reaching USD 14.5 billion by 2028 (Fortune Business Insights). With its innovative technology and expanding market reach, bioAffinity is well-positioned to capitalize on this growing demand and capture a significant share of the market.

Both Enlivex Therapeutics and bioAffinity Technologies have demonstrated strong potential in their respective fields, with promising clinical trial results and regulatory approvals. As these companies continue to make progress, investors can expect to see significant growth and potential breakthroughs in the coming years. The RedChip Small Stocks, Big Money™ show on Bloomberg TV provides an excellent opportunity for investors to learn more about these innovative biotech companies and their potential for future success.